These proceedings are based on a symposium, presented at the European Society of Ophthalmology 2015 Congress in Vienna, Austria on 8 June 2015. The symposium was arranged by Santen to bring together leaders in ophthalmology with the objective of exploring advances in the treatment of severe keratitis in dry eye disease (DED). DED is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance and tear instability with potential damage to the ocular surface. Abnormalities at the ocular surface can affect all tear dynamic components, resulting in a vicious cycle that reinforces/sustains DED. Ciclosporin (CsA) is thought to exert an anti-inflammatory effect on ocular surface cells. This compound should be in the near future one of the principal advances in the treatment of DED for blocking the vicious cycle of the disease. Extensive formulation development work has led to the availability of a well-tolerated, stable cationic nanoemulsion, designated as Novasorb ® technology. This technology has been used in the first European approved CsA 1 mg/mL eye drops emulsion (Ikervis ® ) for the treatment of severe keratitis in adult patients with DED, which has not improved despite treatment with tear substitutes. Clinical trials involving over 900 patients have demonstrated a good safety and tolerability profile and significant clinical efficacy of this formulation with a once-daily dosing regimen. CsA 1 mg/mL eye drops were evaluated in the pivotal phase III SANSIKA study, which confirmed the positive benefit-risk profile of CsA 1 mg/mL eye drops for the treatment of severe keratitis in DED. An assessment of ocular surface health requires: listening to the patient, the use of simple diagnostic tools, an expertise in examination, including use of microscopy, and an up-to-date knowledge of current models of DED.
be used to determine IL-1-receptor antagonist (IL-1Ra), IL-6, IL-8/CXCL8
and epidermal growth factor (EGF), which are elevated in DED patients and correlated with DED criteria.
Any abnormality at the ocular surface can initiate disequilibrium in all other components of tear dynamics, resulting in a series of events constituting a vicious circle that reinforces or sustaining DED (see Figure 1A) . 11 Different therapies act at various points in this vicious circle to inhibit its perpetuation (see Figure 1B ). Agents that have been used to block inflammation include off-label use of steroids, 12 which are associated with major tolerance concerns and off-label doxycycline/minocycline. By contrast, in March 2015, 1 mg/ ml ciclosporin (CsA) (Ikervis ® ) was granted marketing authorisation by the European Commission (EC) for "Treatment of severe keratitis in adult patients with DED, which has not improved despite treatment with tear substitutes." 13 As an immunosuppressive agent belonging to the therapeutic class of ophthalmologicals, CsA blocks the release of proinflammatory cytokines and may exert an anti-inflammatory effect on ocular surface cells. 14 In blocking "the vicious cycle of DED" this compound represents an important improvement in the treatment of the condition. n Vi ra l/ b a c te ri a l co nj un c it iv it is E n v ir o n m e n t C on ta ct len s wear that remain longer at the ocular surface and provide sustained therapeutic concentrations.
Oil-in-water nanoemulsions enable the encapsulation of lipophilic drugs and offer improved stability as well as good tolerability and a high penetration rate (see Figure 2) . 16 The primary endpoint was a composite measure whereby responders were identified if they showed a ≥2 grade improvement in CFS and improvement in OSDI of ≥30 %. There was a higher proportion of responders in the CsA group (28.6 %) compared with vehicle (23.1 %)
although the difference was not statistically significant (see Figure 6 ).
Both the vehicle and the CsA group showed statistically significant improvement in OSDI scores at month 6 compared with baseline; however, the difference between the two groups was not statistically significant. On the planned secondary endpoint of CFS, patients who had received CsA 1 mg/ml showed significantly less staining at months 3 and 6 (p=0.024 and p=0.037) than those who had received vehicle (see Figure 7) . The adjusted mean difference between the two groups in CFS was 0.35 at month 6. 22 To better gauge the clinical relevance of this statistically significant difference, the mean difference can be converted to a ratio in the number of dots on the logarithmic modified Oxford scale. A difference of one grade on the modified Oxford scale corresponds to a multiplication of the number of dots by a factor of 3.16. 23 The exception is the difference between a grade of zero (absence of dots) and Grade I (minimal, 10 dots on the cornea). Therefore, to switch from the mean difference to the ratio of the number of dots, the following formula was used: 
Month 12
Inclusion criteria:
Month 6: Primary ef cacy endpoint CsA 1 mg/ml OD n=154
CsA 1 mg/ml OD n=128 Prescribing Information for Ikervis can be found on page 127
A ratio of 1.50 means that, at month 6, the patients in the vehicle group have on average 50 % more dots compared with the CsA CEm group, and, consequently, 50 % more punctate corneal lesions.
Another method of analysing these CFS data is to compare the frequency distribution of CFS (see Figure 8 ) from baseline to that after Patients who had received CsA CEm showed significantly lower levels of expression of HLA-DR compared with patients who had received vehicle emulsion at Month 1 and Month 6 (see Figure 9 ).
There was no statistically significant difference in OSDI score over time for CsA 1 mg/ml versus vehicle. The mean change from baseline in the 100-point OSDI score was -13.6 with IKERVIS and -14.1 with vehicle at Month 6 (p=0.858).
The main adverse event reported in the SANSIKA study was instillation site pain, of which there was a higher proportion in the Ikervis ® group with 29.2 % (mild: 16.9 %, moderate: 8.4 % and severe: 3.9 %) compared with 8.9 % with vehicle (mild: 4.4 %, moderate 2.2 % and severe 2.2 %) (see Table 1 ) (data on file). Only seven patients had had detectable CsA blood levels (ranging from 0.105 to 1.27 ng/mL) at Month 12 and the values were considered negligible in all cases (data on file) The systemic exposure profile seemed to be consistent with the profile observed until Month 6, whether the patient received CsA for 12 months or was switched to CsA after 6 months of receiving vehicle.
SANSIKA Conclusions
In the SANSIKA study, the severity of keratitis was reduced The correct assessment of ocular surface health is the cornerstone of understanding DED and initiating and maintaining optimal therapy.
Many classic examination tools are available, including history taking, biomicroscopy, tear meniscus, Schirmer's test (I), 24 CFS, conjunctival folds, tear film break-up time and Meibomian gland examination. These are useful to provide an orientation but can be overly time-consuming.
Usually, an assessment begins with simple inspection, which can provide useful information, specifically with regards to epithelial changes, keratitis, inflammation, neovascularisation and the tear meniscus.
However, adequate magnification of the ocular surface is required. Further tests include the measurement of inflammatory markers such as HLA-DR, matrix metallopeptidase (MMP)-9, cytokines and proteomic techniques used to identify protein biomarkers. It is clearly desirable to ensure that accurate diagnosis of DED is ubiquitously available and not only confined it to areas where these advanced diagnostic procedures are readily available. Diagnosis should be affordable, straightforward and quick. Neither is a fixation on assay-derived numbers helpful: a diagnostic gold standard has yet to be developed for DED and cut-off values should not be used in isolation but rather in the context of other assessments.
CFS is a simple, readily available tool that is straightforward in practice. 
